Celcuity To Participate in Upcoming Investor Conferences

Celcuity (Nasdaq: CELC) announced that CEO and co-founder Brian Sullivan will participate in two upcoming investor conferences.

Rhea-AI Summary

Celcuity (Nasdaq: CELC) announced that CEO and co-founder Brian Sullivan will participate in two upcoming investor conferences. He will join a fireside chat at the Wells Fargo 21st Annual Healthcare Conference/b) at 10:15 a.m. EDT on Tuesday, September 8, 2026, and a fireside chat at at 8:00 a.m. EDT on Wednesday, September 9, 2026. Live webcasts for both events will be accessible via conference weblinks and through the Investors section of Celcuity's website, with replays available shortly after the live events.

Argus Sep 1 session 2 alerts

+3.28% close to close 1.8x rel. volume Open Argus

Details

News Market Reaction – CELC

$4.53B Mkt Cap at Peak Alert

On Sep 1, the day this news came out, CELC closed 3.28% above the previous close. Our momentum scanner recorded 2 alerts for this stock that day. Relative volume reached 1.8x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 1 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

• A fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on Tuesday, September 8, 2026. A live webcast will be available using this weblink.
• A fireside chat at Citi's 2026 Biopharma Back to School Summit at 8:00 a.m. EDT on Wednesday, September 9, 2026. A live webcast will be available using this weblink.

Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events.

About Celcuity

Celcuity is a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- locally advanced or metastatic breast cancer (“ABC”), supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine- sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com   
(763) 392-0123  
Jodi Sievers, jsievers@celcuity.com
(415) 494-9924

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Celcuity (CELC) present at the Wells Fargo 21st Annual Healthcare Conference in 2026?

Celcuity will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference at 10:15 a.m. EDT on Tuesday, September 8, 2026. According to Celcuity, CEO Brian Sullivan will present and be available for one-on-one investor meetings.

What time is Celcuity's (CELC) presentation at Citi's 2026 Biopharma Back to School Summit?

Celcuity's fireside chat at Citi's 2026 Biopharma Back to School Summit is scheduled for 8:00 a.m. EDT on Wednesday, September 9, 2026. According to Celcuity, Brian Sullivan will present and be available for investor meetings.

How can investors access the Celcuity (CELC) webcasts for the September 2026 conferences?

Investors can access the live webcasts via the conferences’ weblinks and the Investors section of Celcuity’s website at https://ir.celcuity.com/events-presentations/. According to Celcuity, replay webcasts will be available shortly after the live events.

Will replays be available for Celcuity’s September 2026 investor conference presentations?

Yes, replay webcasts will be available shortly after the live events. According to Celcuity, investors can access these replays from the Investors section of the company’s website following the Wells Fargo and Citi September 2026 fireside chats.

Who will represent Celcuity (CELC) at the September 2026 Wells Fargo and Citi investor conferences?

Celcuity will be represented by Brian Sullivan, its Chief Executive Officer and co-founder. According to Celcuity, he will present at both fireside chats and be available for one-on-one investor meetings with institutional investors.